LIGHT Teaming Profiles
Thank you for showing an interest in ARPA-H’s Lymphatic Imaging, Genomics, and pHenotyping Technologies (LIGHT) program. This page is designed to help facilitate connections between prospective proposers. If either you or your organization are interested in teaming, please submit your information via the form below. Your details will then be added to the list below, which is publicly available.
LIGHT anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the LIGHT solicitation.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
Teaming Profiles List
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Organization name | Point of contact name | Point of contact email | Provide an additional point of contact for your organization's representative (email only) | Location | In 200 words or less, describe your organization's current research focus areas | In 200 words or less, tell us what your organization is looking for in potential teaming partners | Which technical areas within LIGHT does your organization have the capacity to address? |
| Spring Science | Dr. Hope O'Donnell | hope@springscience.com | San Carlos, CA | Spring Science is putting advanced AI image analysis tools in the hands of researchers across a broad spectrum of applications, using cellular or histologic morphology, phenomics, and proteomics to solve complex mechanisms, screen compound libraries, assess clinical biomarkers, develop outcome predictive models, and more. Spring’s expertise in high content imaging, including designing and running assays in house, allows unbiased discovery of novel biomarkers and mechanisms across sample types. Our experience with AI image analysis can benefit all 3 technical areas of this program, allowing multi-modal data comparisons between blood, lymph, and medical imaging data. Custom, web-based AI analysis software tools simplify data sharing across multi-institution collaborations. | Potential partners should have (or intend to have) access to human primary samples, such as frozen PBMC and/or lymph and relevant metadata (eg, test results, disease status, treatment outcomes, etc). For technical area 2, partners should provide medical imaging data. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| Cacta ApS | Ida Groenborg | ida@cacta.dk | mads@cacta.dk | Aarhus, Denmark | We are a Danish University spin-out focusing on developing a home-monitoring solution that empower breast cancer patients to self-measure and make early detection of lymphedema. Keywords are empowerment, user-involvement, digitalization and personalization. | We are in general very open to collaborate, we will be looking for both clinical, regulatory and commercial partners. However the clinical partners (Cancer centers, lymphedema experts, oncologists, surgeons) is the next step for us and we hope for fruitful collaborations that give value for all partners and patients. | Technical area 1: diagnosis and monitoring through biomarker discovery; |
| Imperial College London Department of Bioengineering (Moore Lab) | James E. Moore Jr. | james.moore.jr@imperial.ac.uk | prof.j.moore.jr@gmail.com | London, UK | My research is focused on lymphatic system fluid flow and mass transport. We have developed a MRI-compatible phantom that imitates lymphatic pumping for the purposes of developing better imaging sequences. The phantom provides known pressures, flows and diameters so that accuracy of imaging modalities can be assessed. We can develop similar phantoms for other imaging modalities, e.g., ultrasound. | Imaging experts aiming to develop more quantitative lymphatic imaging modalities capable of assessing physiologic function and pathologic markers. | Technical area 2: imaging technologies; |
| Purdue University | Sulma Mohammed | mohammes@purdue.edu | sulmamohammed@gmail.com | West Lafayette, IN 47906 USA | Lymphatic biomarkers | collaboration | Technical area 1: diagnosis and monitoring through biomarker discovery; |
| The University of Texas MD Anderson Cancer Center | Clifton (Dave) Fuller, MD, PhD | cdfuller@mdanderson.org | CSSharafi@mdanderson.org | Houston, TX | Our group is developing MRI and CT biomarker assessments for post-therapy lymphedema/fibrosis in the head and neck as well as AI-driven models for symptom progression and orphan drug applications for therapy. wit more than 75% of head and neck cancer patients exhibiting lymphedema, we have access to hundreds-to-thousands of annual patients for clinical investigation. | Development partners for engaged technical innovation and transition to actionable patient biomarkers/agents/interventions. | Technical area 2: imaging technologies; |
| Nia Lab, Department of Biomedical Engineering, Boston University | Hadi Nia, Ph.D. | htnia@bu.edu | tavakoli.nia@gmail.com | Boston, MA | We have developed crystal ribcage, with which we are able to image the lymphatic function at the single vessel level in real-time in a functioning lung (functional respiration and circulation). We have developed crystal ribcage for mouse (Nature Methods 2023) and are in the process of developing crystal ribcage for pig and human. Our ongoing directions include developing crystal skull to image lymphatics in brain. | While we develop the imaging technology (e.g., crystal ribcage and crystal skull) and have expertise in the diseases such as cancer and pneumonia, we are looking to apply our technologies to study lymphatic dysfunction in broader conditions that affect the lung and brain. | Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Cornell University Biomedical Engineering | Esak Lee | el767@cornell.edu | elee530@gmail.com | Ithaca, NY | Our research group is leading the development of 3D in vitro models that accurately mimic both the normal functioning and disorders of the lymphatic system. These models encompass initial lymphatic vessels with button-like junctions that facilitate lymph drainage, and collecting lymphatic vessels, which feature zipper-like junctions acting as sound barriers. Additionally, our efforts extend to crafting models of primary and secondary lymphatic valves to study the effects of inflammation on valve functionality. Positioned within specific organs or contexts, these models are pivotal in our understanding of lymphatic diseases that vary by location, such as lymphedema, rheumatoid arthritis, glaucoma, neurodegenerative diseases, and cancer. To bolster our findings from these chip-based models, we also create and utilize corresponding in vivo models for validation. Our work is generously funded by two R01 grants and three R21 grants, along with crucial support from the National Institutes of Health (NIH), including the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID). For more information, please visit our website at https://leelab.bme.cornell.edu. | We are looking for potential teaming partners in the Technical area 1 and 2. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Triple Ring Technologies | Roger Tang, PhD | rtang@tripleringtech.com | shemami@tripleringtech.com | Newark, California | We strive to be the most trusted partner for developing science-driven products in medtech, life sciences, and sustainability. In this role, we choose fulfilling problems, take on significant challenges, pull together diverse teams, collaborate fearlessly, and have a positive impact on people and the planet. To accomplish this vision, Triple Ring Technologies has assembled an interdisciplinary team of scientists, engineers, developers, and designers (25% with PhDs) that specializes in accelerating technologies up the TRL scale. Triple Ring Technologies specializes in taking technology ideas and benchtop demonstrations from concept to prototype (including for clinical use), and we have extensive experience with designing and commercializing complex medical devices and life sciences tools, including medical imaging and radiation therapy systems. Examples that highlight our relevant experience include: • Imaging systems (multiple platforms and clients) o CT scanners for medical, animal health, research, and industrial applications o Novel imaging modalities using electromagnetic interactions o Gantry and imaging platform design • Biomedical and optical systems (multiple projects) o Various tissue oximetry systems o High speed fluorescence and fluorescence lifetime scanning systems o Stereotactic visualization system • Medical robotic systems o MRI compatible robot for advanced brain biopsy o Various robotic platforms for imaging and surgery | We stand side-by-side with innovators and entrepreneurs to solve hard problems, launch breakthrough products, and create new businesses. We can provide the concept realization and technology development for FDA submission, clinical testing, and/or commercialization. We can start with just a concept (e.g., background intellectual property, or even just an idea); at the other end of the TRL scale, we can design or redesign for manufacturing or for FDA submission. Teaming partners would bring medical expertise, clinical experience, other technologies required, and big ideas that are not constrained by what they think is limiting in today’s technology. Prior experience in creating novel technology is not required. | Technical area 2: imaging technologies; |
| BevelCloud, Inc. | Julee Sung | julee@bevelcloud.io | tim@bevelcloud.io | Marina del Rey, CA | Creating accurate diagnostics requires access to large amounts of diverse multimodal data. This data is available in real-time from clinical machines (e.g. imaging machines, blood analysis), research machines (e.g. sequencers, mass spectrometers), offline data and from PACS and EMR applications – all in the building at a clinic, hospital or research labs. Unfortunately, the traditional centralized approach to analyzing this data will not work in medicine. The data sets are large so who pays for the network bandwidth? Schemas for these data warehouses are rigid and are difficult to agree on. ETL and data cleansing is expensive and difficult. Privacy management is a challenge. Centralized architectures create a larger attack surface. They are not scalable or extensible. BevelCloud has developed a real-time, privacy-preserving, scalable decentralized in- the-building edge cloud service and deployed in 8 hospitals on 3 continents. Using clinical machine, research machine, PACS and EMR digital twins the platform uniformly standardizes data in all clinics, hospitals, and research labs. Furthermore, using fine-grained access control the platform enables authorized applications to access the data – in the building. Applications can transfer, infer or learn on the data in the building using federated learning software where no data ever leaves the building. | BevelCloud has built the technology infrastructure and gone thru security and privacy reviews – all required to deploy the platform in the building. We are looking for application teaming partners who have domain expertise in lymphatic diseases · Develop software application to improve diagnosis and monitoring through biomarker discovery. · Develop software applications, deployed to the point of care to improve imaging technologies · Develop software application to aid in the prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction. We believe together we can develop novel diagnostic approaches which can significantly improve patient care and outcomes. Teaming partners could include · Clinicians who are interested in a discovering a new biomarker, or developing a new diagnostic or prediction application using the latest AI and cloud computing technologies. Teaming partners could include · Independent software vendors (ISVs) who have both clinical and software expertise but lack access to data from clinical machines, research machines, PACS and EMRs. · Consulting groups who may or may not have clinical expertise but have experience in developing software in the healthcare field. Based on our work to date we have excellent relationships with a number of leading healthcare providers. | Technical area 2: imaging technologies; |
| LipoCheck | Helena Rapprich | helena@lipocheck.de | anina@lipocheck.de | Berlin, Germany | Our organization's current research focus areas center around developing a multimodal AI system aimed at measuring objective diagnostic criteria for lipedema. This innovative system integrates various data sources and technologies to accurately diagnose and monitor lipedema, a condition characterized by abnormal fat distribution. Through advanced AI algorithms, we analyze medical images, patient-reported symptoms, and clinical data to identify patterns indicative of lipedema onset and progression. Our research aims to revolutionize lipedema diagnosis by providing healthcare professionals with a comprehensive and reliable toolset for early detection and personalized treatment planning. By leveraging machine learning and image processing techniques, our system can quantify key diagnostic indicators, such as tissue composition, fluid retention, and inflammation levels, with high precision and efficiency. | Our ideal partners are committed to advancing the field of lipedema diagnosis and treatment, with a focus on improving patient outcomes and addressing unmet needs in healthcare delivery. We value collaborators who bring diverse expertise and perspectives to the table, whether in AI development, medical research, clinical testing etc. | Technical area 2: imaging technologies; |
| Beth Israel Deaconess Medical Center | katja de paepe | kdepaepe@bidmc.hardvard.edu | Boston, MA | My current focus of research is to investigate the imaging appearances of the hepatic lymphatics using routine cross-sectional imaging techniques, ie CT and MRI, across different stages of chronic liver disease and to correlate these with clinically significant paramters and patient outcome | We would be particularly interested partners from the hepatology or pathology field to correlate our findings with new lymphatic markers they are developing. Additionally, we would also be interested to find other imaging partners for validation studies of the imaging findings or collaborate to explore new imaging markers of chronic liver disease | Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| Foundation to Advance Vascular Cures | Isabel Bjork | vcadmin@vascularcures.org | lherath@vascularcures.org | Redwood City, CA | We are dedicated to bringing patient partners to the research table as advisors and equal decision-makers. Studies show that early and frequent patient engagement is beneficial to research. This kind of engagement informs the methods, tools, endpoints, outcomes, and other facets of research studies which often do not resonate with patients. We recruit, train, and support patients with conditions like lymphedema to work alongside researchers. These patient advisors provide their insight and feedback on objectives, methodologies, and other aspects of research studies, better aligning outcomes with actual patient needs and preferences. Our current research focus area is therefore patient-centered research on vascular conditions, with patient partners at the forefront. | We are looking for partners that are interested in authentic patient engagement, and who are looking to benefit from the inclusion of patients on their research team. We have existing patient partners with lymphedema, and have an effective recruitment and training structure in place to onboard more patients with lymphedema to advise on research. Research partners will provide guidance on the knowledge and skills patient partners need to be equal advisors, and we work one-on-one with patient partners to bring them to that level and support their ongoing involvement in research studies. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction;Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies; |
| University of Texas Southwestern Medical Center | Benjamin Levi | Benjamin.Levi@utsouthwestern.edu | Dallas, TX | Our research team has expertise and interest on the role of lymphatics on musculoskeletal injury, repair and regeneration. Specifically, we focus on understanding the role and interaction of lymphatics with local progenitor cells and myeloid cells to guide tissue repair, fibrosis and regeneration. We have expertise in models of muscle, tendon and bone injury and regeneration. Technically we have expertise in lineage tracing, single cell and spatial transcriptomics and metabolomics. | Our team is looking for partners in imaging to assess lymphatic function. While we have shown lymphatic regeneration after musculoskeletal injury, having a partner with expertise on the function of these new lymphatics would help advance the science. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| Tesorai Inc. | Melissa Miao | melissa@tesorai.com | Grants@tesorai.com | San Diego, CA | Tesorai is a top-tier AI team (former Alphabet and Meta) building applications that accelerate life science research efforts. Tesorai’s AI/ML platform is focused on increasing the success of scientific discovery projects primarily focused on Mass Spectrometry based Proteomics and Metabolomics. Some of our focus areas are: - Preprocessing of mass spectrometry proteomics data: Identify significantly more analytes from the raw spectra in a given sample that are missed today, in a fraction of the time that it takes the current software. - Identification of biologically relevant hits in high-throughput assays: Reduce batch and plate effects to significantly improve false-positive and false-negative hits. - Multi-omics model that understands biology: Model cellular biology to reduce the dimensionality of life-science data, and facilitate the success of biological discoveries | Tesorai is looking for partners, who are interested in biomarker discovery with clinical and translational research expertise in LD and Lymphatic biology or interested in studying the role of the lymphatic system in other diseases. Groups planning for mass-spec proteomics experiments or have access to existing biological samples for MS proteomics or have existing proteomics datasets would be a great partner. | Technical area 1: diagnosis and monitoring through biomarker discovery; |
| UMass M2D2 | Alexei Teague | alexei_teague@uml.edu | maryann_picard@uml.edu | Lowell, MA | UMass M2D2 is a medtech/biotech startup incubator and accelerator that is a collaboration between UMass Lowell and UMass Chan Medical School. We provide a host of different business development services that are needed to advance startup companies, from regulatory guidance, help with IP, connections with venture capitalists, to tax guidance. These are just a few of the services our program offers, in addition to physical lab space on both the UMass Lowell and UMass Chan Medical School campuses. In addition, using the resources of both UMass Lowell and UMass Chan Medical School, M2D2 has access to world class researchers and students who are eager to be involved in the innovation community. | We are looking for potential partners who need the resources of a research academic institution (UMass Lowell), a medical school (UMass Chan Medical School), and a medtech/biotech incubator and accelerator (UMass M2D2). Our three combined organizations are looking for entrepreneurs who have a technology that addresses the ARPA-H area of interest, but need partners who can support both their company with business development (reimbursement, IP, regulatory, etc.) and their innovation (research collaboration with professors and students). | Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery; |
| Inkwell Health Ltd. | John Matthews | jmatthews@inkwellhealth.com | support@inkwellhealth.com | Ontario, Canada | Inkwell Health has developed a patent pending, cutting edge solution to remotely monitor swelling, range of motion and temperature of patients after surgery or injury. The product is a medical device and the knee module is currently on the market in the US. The company is now in the process of developing a solution to remotely monitor patients suffering from lower leg lymphedema and is looking for development and research partners in this area. Inkwell is also interested in collaborating with experts in this field who could potentially use this remote monitoring solution to further their research in this area. | Inkwell Health is in the late stages of developing a version of their system that would enable patients to remotely monitor lower leg lymphedema (or swelling) and is looking for potential development, testing and research partners. Specifically, Inkwell is looking for partners who may be interested in both testing this solution, as well as using the system to further their research efforts in this area. Lastly, Inkwell would also be interested in validation and publication partnerships with experts in this area. | Technical area 2: imaging technologies; |
| CFD Research Corp. | Andrzej Przekwas, PhD, CTO | andrzej.przekwas@cfd-research.com | adam.hott@cfd-research.com | Huntsville AL | CFD Research has developed unique multiscale-computational modeling tools, CoBi, for modeling lymph flow using medical image reconstructed lymphatic system. The anatomical geometry of the lymphatic system is represented using a quasi 3D (Q3D) model and simulates the peristaltic lymph flow and transport of fluids, immune cells and molecular entities (antigens, antibodies, cytokines, nanoparticles, tracers, …). Individual lymph nodes are represented as multicompartmental regions (sinuses, germinal center, B-cell follicle, T-cell region and blood perfusion). The lymphatic system flow model is coupled to the whole body vascular circulation model (in the “streamwise” direction) and to the surrounding tissue/organs enabling absorption from, and leakage to the “backflow” in the interstitial fluids. This coupled model enables kinetic simulations of fluids, biomarkers, tracers and therapeutics. For example, it can predict spatial-temporal distribution of a tracer delivered to a specific depot (e.g. subcutaneous or microneedle) to identify optimal timing for imaging. CoBi multiphysics “engine” can be used to simulate the physics of the lymphatic imaging (e.g. the near -infrared fluorescence lymphatic imaging) linked to the kinetics and biodistribution of the fluorescent tracers | In the LIGHT project we could adapt and provide our CoBi tools (open source) and existing models to support various aspects of the project, including 1) automated generation of quasi 3D (Q3D) of lymphatic vessels/nodes from medical imaging for modeling lymphatic transport, physiology, immunology, pathology and targeted therapeutics 2) whole-body systemic-lymphatic transport and pharmacokinetics on novel tracers (liposomes, microbubbles, nanosponges…), Our CoBi multi-bio-physics software tools, coupled systemic-lymphatic modeling and quantitative systems pharmacology capabilities could support TA1 – Modeling Biomarker Kinetics (BxK) of the lymphatic disease specific biomarkers – generation, biodistribution, elimination and optimal sampling, TA2 – Generation of quasi 3D (Q3D) of lymphatic vessels/nodes from medical imaging for modeling lymphatic transport, physiology, immunology, pathology and targeted therapeutics TA3 – Incorporation of various risk factors (genetic/epigenetic, anatomical, comorbidities) into computational models of lymphatic diseases. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Weinberg Medical Physics, Inc. | Irving Weinberg MD PhD | inweinberg@gmail.com | Rockville, Maryland | We develop novel compact image-guided therapy systems, appropriate for use in small offices or homes. With respect to the LIGHT topic, we propose to utilize a novel compact single-sided imaging system (using magnetohydrodynamic pumping (supplemented with fast induction coils) to visualize lymphatics and to augment flow in pathological states. | Animal and phantom models of lymphatic disease and sites for pilot human studies in lymphatic and glymphatic drainage. | Technical area 2: imaging technologies; | |
| AtlasXomics Inc. | Ken Wang | kenw@atlasxomics.com | jeffreys@atlasxomics.com | New Haven, CT | AtlasXomics provides commercial spatial multi-omics assays for researchers in cancer, neurodegenerative and cardiovascular diseases as well as aging. Our platform Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq) is based on microfluidics and next generation sequencing (NGS). Our research efforts are focused on democratizing first-to-market spatial epigenome assays for chromatin accessibility and histone modifications. We are seeking to continue delivering exponential increases in data/dollar to customers through new generations of chip design and declining costs of NGS. At present, our assays work with fresh frozen tissue sections. Current research is focused on extending the platform through new products such as co-profiling (whole transcriptome and epigenome) and through the flexibility to interrogate formalin-fixed, paraffin-embedded (FFPE) tissue. | Our team is keen to work with other groups where we contribute to LIGHT’s mission. Epigenomic profiling of lymphatic vessels from control and treated subjects would provide a novel layer of data to provide insight for preclinical and translational researchers. We are especially interested in working with partners that have goals and experience in moving quickly from insight to clinical stage. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction;Technical area 1: diagnosis and monitoring through biomarker discovery; |
| Thomas Jefferson University | Priscilla Machado | priscilla.machado@jefferson.edu | flemming.forsberg@jefferson.edu | Philadelphia, PA | The use of contrast-enhanced ultrasound and ultrasound imaging to evaluate sentinel lymph nodes in patients with breast cancer. We also expanded to patients with esophageal and lower tract genital cancers. We are also start to work on sentinel lymph node characterization, the use of AI and kinetics models to the development of biomarkers. | We are looking for partners which are also interested in using ultrasound imaging to the evaluation and characterization on sentinel lymph nodes and that want to move this field forward on order to determine biomarkers and promote improvement in patient care. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| University of South Florida | Jerome Breslin | breslin@usf.edu | laurelis@usf.edu | Tampa, FL | Our laboratory has specialized in isolating lymphatic vessels to study pump function for two decades. Most of our work has been done with rodent models, but a few years ago, our institution formed a partnership with a local organ transplant organization, LifeLink, making non-transplantable organs available for research. Leveraging this partnership, we have developed protocols to isolate mesenteric collecting lymphatics vessels and study pump function in vitro. We also developed protocols to isolate mesenteric tissue and perform transcriptomic analysis using single-nucleus next-generation sequencing (snRNA-Seq), providing snapshots of lymphatic endothelial cells and other cell types present in both healthy and diseased tissue. Our current research is exploring how obesity and diabetes impair the lymphatic system, so we have used both the tools to study function (pumping) and the transcriptome (snRNA-Seq) to investigate mechanisms by which these metabolic disorders lead to poor lymph transport. We are also starting a project to investigate potential changes in the transcriptome of women who develop breast cancer related lymphedema, in collaboration with our plastic surgery department that performs immediate lymphatic reconstruction at the time of breast cancer surgery. | We currently have access to internal organs and the ability to build a transcriptomic atlas of lymphatics isolated from these organs. We are also embarking on a study that will involve patients with secondary lymphedema. However, it would be good to partner with others who work directly with primary lymphedema patients that might donate tissues that would be otherwise discarded as part of a medical procedure. Such parternships could potentially lead to development of a human lymphedema transcriptomic atlas that could be useful for identifying druggable targets to help drive lymphatic function and alleviate symptoms. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Department of Radiology, Thomas Jefferson University | Flemming Forsberg | flemming.forsberg@jefferson.edu | priscilla.machado@jefferson.edu | Philadelphia, PA | All aspects of ultrasound technology and imaging with a focus on ultrasound contrast agents specifically for use as lymphatic tracers. | Laboratories that compliment our ultrasound imaging expertise. | Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery; |
| MagniKeen Inc. | Henning Schroeder | HenningSchroeder@MagniKeen.onmicrosoft.com | StefanGloeggler@MagniKeen.onmicrosoft.com | Needham, MA | We have developed a rapid signal-enhancement approach for MRI that uses body own metabolites as contrast agents and allows the direct readout of metabolic changes. Our focus is to establish our unique approach to image the lymphatic system and to: 1) deliver an imaging tool for differential diagnostics of lymphedema, lymphatic anomalies and lipedema 2) deliver unprecedented readout of metabolic changes in patients for diagnostics and treatment response 3) make our contrast agent technology widely-applicable for all MRI systems | We are looking for: 1) clinical and pre-clinical collaborators to test and implement our technology in models and patients 2) complementary imaging techniques 3) complementary expertise in developing biomarkers 4) AI experts to collaborate on improving image quality | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies; |
| University of the Pacific, Thomas J. Long School of Pharmacy, Department of Physiology and Pharmacology | Atefeh Rabiee | arabiee@pacific.edu | Stockton, California | Expertise in cell and molecular biology and physiology, Omics technology (Mass Spectrometry based) Currently focusing on Lipedema | Clinicians with access to patients' biopsies, imaging technologists, Lymphatic experts | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| Duke University | Tuan Vo-Dinh | tuan.vodinh@duke.edu | kpho@duke.edu | Durham, North Carolina | Our research activities have focused on developing novel molecular sensing technologies through genomic biomarker discovery (DNA, miRNAs, mRNAs). For example, our “Inverse Molecular Sentinel” (iMS) biosensor can detect selected microRNA (miRNA) biomarkers, and our “Nanorattle” lab-on-a-stick assay can monitor mRNA biomarkers directly in human samples (tissue, blood, saliva) without the need for lab-based sample treatment and amplification. The molecular biosensing technologies developed in our lab would have broad-based diagnostic applications for a wide variety of diseases ranging from cancer to cardiovascular, infectious, and lymphatic diseases. Specific miRNAs are often differentially expressed in primary lymphatic diseases (LDs) and can serve as early diagnostic markers, even before clinical symptoms. Our molecular diagnostics platforms will move these miRNA tests from the traditional lab-based quantitative reverse transcription-polymerase chain reaction (qRT-PCR), microarrays, and next-generation sequencing assay schemes to novel molecular analysis platforms that are simpler, more cost-effective for medical research capable of enhancing research in the areas of early detection and screening, understanding the pathophysiological mechanisms underlying these conditions, and ultimately developing effective targeted therapies. | We are interested in collaborating with partners who share our passion for innovation and have expertise in complementary fields related to lymphatic diseases. Your complementary expertise, either in fundamental research or translational applications, and our innovative molecular sensing development can make a significant impact in healthcare. By combining our strengths, we cannot only accelerate the development and application of our research findings but also create a synergy that will benefit patients and healthcare providers. | Technical area 1: diagnosis and monitoring through biomarker discovery; |
| University of Texas Health Science Center | Eva Sevick, John Rasmussen, Melissa Aldrich | Eva.Sevick@uth.tmc.edu; john.rasmussen@uth.tmc.edu; melissa.b.aldrich@uth.tmc.edu | Maria.D.GarciaVillarreal@uth.tmc.edu | Houston, Texas | Our team has made several discoveries using clinical near-infrared fluorescence lymphatic imaging (NIRF-LI) studies of 800+ infants, children, and adults under IRB and FDA investigational drug/device approvals. Now, it is time to make our technology available for others to make discoveries. In doing so, we will establish a database that can be utilized to develop evidence-based clinical practices leading to lymphatic health. While we have begun ISO manufacturing with a commercial team, our current focus is to standardize acquisition of imaging data as well as to develop big data approaches for automated image analyses via machine learning and accurate phenotyping for genomics/biomarker discovery. | We are looking for clinical partners/advocacy groups who would (i) conduct human studies using NIRF-LI devices under investigational approvals from a common IRB and FDA investigational application, (ii) acquire and upload imaging data into a common database for automated analysis, and (iii) use imaging to accurate phenotype lymphatic dys(function) for genomic and biomarker discovery. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Teledyne Scientific and Imaging, Intelligent Systems Laboratory | Michael Weisend | michael.weisend@teledyne.com | patrick.connolly@teledyne.com | Research Triangle Park, NC, USA | Our strengths are artificial intelligence, machine learning, autonomy, control systems, and algorithm development as they apply to target recognition and tracking, novel neuroscience applications (sleep, brain computer interface, neuromodulation), and human performance enhancement. | We are partnered with Teledyne DALSA and will bring novel novel imaging via CT and Magnetism with the appropriate image processing and analysis. We need medical personnel to help us focus on and understand a relevant use case(s). | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| University of Rochester, NY | Rashad Hussain | rashad_hussain@urmc.rochester.edu | sshield4@ur.rochester.edu | 601 Elmwood Ave, Box645, Rochester, NY | Our recent findings suggest that head edema resulting from injury is accompanied by dysfunction of lymphatic vessels in the neck region. We devised the most advanced imaging modality as well as refined a pharmacological approach to counteract the edema resulting from injury. Our high-speed/high-resolution 2-photon scans provided substantial insight into the fluid flow dynamics of the lymphatic vessels. Intriguingly, high levels of noradrenaline play a crucial role in the development of edema. Neutralizing the spikes of noradrenaline which are evident in blood plasma, by pan-adrenergic inhibitors (PPA) significantly down-regulates the edema. We leverage our advanced imaging approach and AI-assisted analytical strategy giving us pivotal insight into the contraction rhythms and fluid transfer by lymphatic vessels, to propose a solution for lymphedema in trauma/injury, cardiovascular disorders (i.e. vein thrombosis, etc.), and autoimmune/Inflammation. | We Look for partnering lab with interest/expertise in non-invasive lymphatic imaging. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Elegant Mathematics LLC | Ilgis Ibragimov | ii@elegant-mathematics.com | Saarbruecken, Germany | MR NIB: Magnetic Resonance Non-Invasive Beam Our team is developing a rapid, simple, and portable diagnostic system based on nuclear magnetic resonance methods with angiography. Our approach allows for the miniaturization of MRI equipment and significantly simplifies imaging without using complex T1/T2 sequences. By employing Dynamic Nuclear Polarization (DNP) in our method, we can pre-polarize internal fluids and track their movement, thereby achieving angiography without any intravenous injections. For our portable MRI technology, we have developed a special magnetic material (US10646722B2), a unique device for creating combined DNP-NMR radiation (US10773092B2), and we possess innovative methods for capturing MRI signals (US10773093B2) and a method for combined DNP-NMR (DNP-MRI) excitation (US11707634B2). Our company also develops and manufactures computer vision systems, which we utilize in the DARPA Triage Challenge at Systems Competition. These systems enable real-time computation of the portable MRI's position relative to the measured object, allowing us to merge MRI scans of adjacent organs in real-time and monitor changes in the same organ over the long term. | We have all the necessary technologies, resources, a motivated team, and industrial capabilities to create the first prototypes of portable MRI devices. Following tests and certifications, we aim to commence production. We are also open to any mutually beneficial collaborations on the LIGHT project. | Technical area 2: imaging technologies; | |
| Wellman Center for Photomedicine, Mass General Hospital (Prof. Brett Bouma Lab) | David Veysset | dveysset@mgh.harvard.edu | Boston, MA | We specialize in the development of innovative optical imaging technologies for clinical applications (https://octresearch.org/). We are currently developing a photoacoustic platform for deep tissue imaging using original affordable laser sources that are clinically viable. See for example: H. Lee, et al., Photoacoustics 25, 100331 (2022) and H. Lee, et al., Laser & Photonics Reviews, 2400144 (2024). We believe this imaging modality can enable deep selective imaging of the lymphatic system and advance the diagnosis and monitoring of lymphatic diseases such as lipedema in a cost-effective highly deployable manner. | Our lab has a long track record of productive collaborations. We are looking for partners with: - expertise in lymphatic pathologies - expertise in lymphatic system imaging - experience in ultrasound imaging, including phantom development for lymphatic disease models, image reconstruction, AI-based diagnosis - experience in technological transition - experience in regulations and commercialization Our team would be a good fit for partners aiming to propose ultrasound-based imaging technologies and who are interested in developing photoacoustics where our team would design clinically viable, commercially sound, highly deployable laser sources. | Technical area 2: imaging technologies; | |
| University of Minnesota | Linda Koehler | koeh0139@umn.edu | Minneapolis, Minnesota | Our current research focuses on early detection of breast cancer related lymphedema using a multimodal approach including bioimpedance (clinical and home devices), ultrasound imaging, tissue dielectric constant measures, girth measures, and patient reported outcomes. We are also working on the development of a new device to measure fibrosis. We are an academic research institution with access to patients with all stages of lymphedema. | Partners with the vision of combining and advancing a multimodal approach with the goal of having the comprehensive lymphedema diagnostic solution be patient oriented, accessible, and cost effective. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies; | |
| Georgia Institute of Technology | Susan Thomas | susan.thomas@gatech.edu | Atlanta, GA | Lymphatic drug delivery technologies. We have developed a biosafe delivery system that uniquely allows diagnostic and therapeutic agents to be delivered to lymphatic tissues for sustained times after injection to uniquely activate lymphatic functions, that is easy to use, easy to store, and can be paired with a variety of payloads. We have also developed unique systems that can quantify mechanisms of lymphatic transport, which can benefit quantification and classification the type of function or dysfunction in the lymphatic system. | We are looking for partners who have novel imaging agents or therapeutics that would benefit from a technology that can deliver them into the lymphatic system. | Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| Australian Lymphoedema Education, Research and Treatment (ALERT) Program Department of Health Sciences Faculty of Medicine, Health and Human Sciences Macquarie University | Associate Professor Hiroo Suami | hiroo.suami@mq.edu.au | louise.koelmeyer@mq.edu.au | Sydny, New South Wales, AUSTRALIA | ALERT focuses on clinical observatory research in individuals with lymphatic disease, predominantly primary and secondary lymphedema. We employ cutting-edge technologies, such as bioimpedance spectroscopy (BIS) and indocyanine green (ICG) lymphography, for research into early diagnosis and intervention of lymphedema. Our anatomical specialist mapped the lymphatics in a human cadaver model therefore we have the advantage of greater understanding of baseline images of normal lymphatic anatomy and altered lymphatic anatomy in lymphedema. We have conducted over 1,000 ICG lymphography assessments on individuals to detect primary lymphedema, secondary cancer, and secondary non-cancer related lymphedema and published ICG lymphography protocol papers for imaging assessment of lymphedema in different body regions. Lymphatic mapping continues to be a focus of the ALERT program and to overcome ICG lymphography's limitations in visualizing only superficial lymphatics, we aim to enhance our understanding of lymphatic anatomy by selectively injecting contrast media into lymphatic vessels. This innovative new technique will provide a dynamic diagnostic modality, permitting effective evaluation of anatomical and functional status of lymphatic vessels, that is as portable as ICG lymphography and as capable of imaging deeper lymphatics as MRI lymphangiography. Initially, we will conduct preclinical studies using cadaver models before translating the technique to patient care. | We are looking for potential partners who have the following expertise: • Producing nano-contrast media for MR Lymphography. • Experience with contrast-enhanced MR or CT Lymphography. • Able to perform imaging studies in clinical settings. We welcome teams from organizations that wish to utilize our anatomical mapping information of the lymphatics in human and animal cadaver models and individuals with lymphedema and other lymphatic disorders. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies; |
| Droplet Biosciences | Wendy Winckler | wwinckler@dropletbiosci.com | Cambridge, MA | Droplet has pioneered a novel platform to harvest and profile patient lymphatic exudate collected immediately after cancer resection surgery. Our lymph-based diagnostic assay queries the environment that underlies the body’s immune response, offering the earliest, most precise, and most actionable data about cancer. Droplet’s core product is a lymph liquid biopsy that detects residual cancer 24 hours after surgery with higher sensitivity than traditional pathology and blood-based liquid biopsies. Droplet returns results early enough to influence adjuvant treatment decisions and can even predict recurrence in patients who are node-negative, enabling care teams to match treatment to the patients who need it. Droplet offers a non-invasive window into the tumor microenvironment. In addition to the ctDNA that signals the presence of disease, lymph contains important biomarkers including immune cells, proteins, and metabolites that can bring novel insights to areas such as target discovery, patient selection, and treatment response. | We would be interested in partnering with teams that have access to disease or healthy patient lymphatic-associated fluid or tissue samples. We would also be looking for partners with sample characterization platforms and expertise that complement ours. | Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| BioCytics | Brent Dixon, PhD | bdixon@biocytics.com | rwarin@biocytics.com | Huntersville, NC | BioCytics, Inc., founded in 2005, has a focused mission to directly apply living cells in clinical trials as affordable individualized immune cellular therapies manufactured at the Point of Care (PoC). It is the only independent, privately held, warm-chain PoC cellular manufacturing facility in the US. Its affiliate, Carolina BioOncology Institute, PLLC (CBOI) is co-located adjacent to BioCytics Good Manufacturing Practices (GMP) facility. BioCytics’ fully vertically integrated Human Applications Laboratory (HAL), capable of producing maximally fit immune cells for optimized solid tumor agnostic (pan-cancer) therapeutics with a proprietary Warm-Chain PoC Manufacturing and Individualized Autologous Adaptive Cellular Therapy (AACT) Platform and assays to identify the most effective patient specific/individualized immune cell therapy, leveraging circulating tumor cells (CTCs)/tumor derived cell clusters (TDCCs) and patient derived tumor organoids (PDTOs). BioCytics-CBOI infrastructure forms a fully integrated platform to collect a patient’s immune cells, blood draw or leukapheresis, immediately transferred to the adjacent GMP compliant HAL for AACT. BioCytics HAL is a revolutionary manufacturing platform to generate cells with the highest specificity, functionality and durability. We support longitudinal tumor biomarker measurements. BioCytics digital technology of machine learning feedback algorithms are enabled by OpenEHR & OpenDICE/BioDICE opensource collaborative space for developing and integration of Evolutionary Trial Design. | BioCytics is seeking to collaborate with experts in imaging technologies, genetics, and epigenetics to integrate with/leverage our core capabilities to provide a well-rounded comprehensive solution. BioCytics partners with cancer and immunology researchers to advance cancer and immunology research through its biospecimen sourcing efforts. We are looking for collaborators and researchers who need leukapheresis immune cells, or circulating tumor cells (CTCs), tumor derived cell clusters (TDCCs) and patient derived tumor organoids (PDTOs). We can provide GMP process optimization and scale up for manufacturing clinical trial cell therapy investigational product and CDMO / CRO services including IND drafting and submission to FDA for phase 1 clinical trials. We want to partner with collaborators and study sponsors who need a Phase 1 clinical trial site for pan-cancer solid tumor cell therapies. BioCytics offers translational research services leveraging its cellular biology labs including advanced equipment including flow cytometry, video microscopy, impedance cytotoxicity assays and custom assays. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Sofusa Inc. | Rusty Ross | rross@vivasor.com | Atlanta, GA | Sofusa is a drug/device company developing lymphatic targeted therapies for improved treatment of autoimmune diseases and cancer. Sofusa has recently completed two Phase 1b studies in RA and CTCL with very promising results in relapsed/refractory patients, demonstrating the potential of the lymphatic system to be a more effective target for treating and understanding some diseases. Our research is focused on two areas: (1) developing new drugs with disease targets in the lymphatic system and lymph nodes versus traditional systemic approaches, and (2) developing MRI based techniques for full-body lymphatic imaging using the continuous lymphatic delivery device developed by Sofusa. The device enables us to study lymphatic function and disease over time and under different kinetics and stages in disease progression. The ability to continuously deliver imaging agents at controlled rates and periods of time should more effectively help us study lymphatic function than standard bolus injection techniques. | Sofusa is looking for partners and/or collaborators who can help identify therapeutic targets in the pathogenesis of diseases that exist and progress in the lymphatic system and lymph nodes. We are also very interested in broad perspectives as we continue to develop MRI lymphatic imaging techniques. Lymphatic imaging is a highly complex experimental technique, and the effort would benefit from a strong and experienced team. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies; | |
| Revi Life Sciences | Jason Eades | jason@revilifesciences.com | adri@revilifesciences.com | Austin, TX | Revi Life Sciences is an organ-on-a-chip company specializing in lymphatic dysfunction biomarker discovery. The team features molecular biologists, AI/ML developers, microphysiological systems engineers, preclinical lymphatic physiologists, molecular labeling chemists, and lymphatic vascular clinical specialists studying human lymphatic physiology and pathophysiology. It includes advisors with deep drug discovery, translation and clinical development expertise. The company has a collection of multi-omics datasets from patient tissue samples with secondary lymphatic dysfunctions and organ specific lymphatic dysfunction. Revi integrates these multi-omics data with human microphysiological analysis, histopathological assessments, and animal disease models and use proprietary AI/ML approaches to identify prospective biomarkers with high translational potential. Revi intends to develop novel imaging probe and use multiple cutting-edge imaging-based labeling methodologies and technologies with the goal of developing novel imaging modalities to diagnosis lymphatic aberrations. The company has a suite of lymphatic disease models, which have been published in peer-reviewed research including animal models and revolutionary complex in vitro models of lymphatic vasculature that mimic human lymphatic diseases and can be used for clinical translation. Finally, our clinical advisory group are from reputable clinical lymphedema care centers and provide critical guidance on maximizing the translational potential of novel biomarker. | We are seeking collaborations with organization with imaging technology expertise. Organizations which proficiency in theranostic imaging customization and image guided therapy for PET/SPECT, MR techniques, magnetic particle, fluorescence and bioluminescence will be ideal. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Seoul National University | Noo Li Jeon | njeon@snu.ac.kr | Seoul, Republic of Korea | working in high-throughput MPS (microphysiological systems) models with ability to form lymphatic vessel networks reliably. This model can be used for testing new imaging contrast agents, biomarker discover, and lymphatic dysfunction models | users who can utilize in-vitro model of perfusable lymphatic vessel networks which can be modulated with flow as well as genetic modifications to build different patholgical models of lymphatic dysfunction | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction;Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| UCLA | Ellen Sletten | sletten@chem.ucla.edu | Los Angeles, CA | Non-invasive in vivo multicolor imaging in the shortwave infrared region of the electromagnetic spectrum. Our primary expertise is in the development of fluorophores. | We would love to partner with biologists as well as those on the technology development side of optical imaging to help bring our fluorophores into people. | Technical area 2: imaging technologies; | |
| Massachusetts Institute of Technology/Massachusetts General Hospital | Galit Frydman | gfrydman@mit.edu | gfrydman@mgb.org | Cambridge, MA | Experience in inflammation/immunity, infectious disease, coagulopathy. Experience in product development and design of novel medical devices and diagnostics, microfluidics (precision medicine + precision engineering). Collaborative work between MIT Dept. of Biological Engineering, Division of Comparative Medicine, Dept. of Mechanical Engineering and MGH Dept. of Surgery. | We are interested in developing a sample collection device to enable the collection of lymphatic fluid samples without the need for terminal procedures in animal models and also to be translatable to humans for research and future diagnostic purposes. Would like to work with a group performing sample analysis and biomarker discovery. | Technical area 1: diagnosis and monitoring through biomarker discovery; |
| The Broad Institute of MIT and Harvard - Machine Learning for Health | Mahnaz Maddah, PhD | maddah@broadinstitute.org | Cambridge, MA | Machine Learning for Health (ML4H) is a team of Broad Institute machine learning scientists and engineers who, in collaboration with faculty members and clinicians from Massachusetts General Hospital, Brigham and Women’s Hospital, MIT, and Harvard, develop machine learning methods for biology discovery, diagnosis, disease subgroup classification, and risk prediction, with applications in clinical trials and clinical decision support. | We are interested in collaborations that leverage our experience in clinical AI and genomics for the aims of the LIGHT program | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| Northeastern University | Deniz Erdogmus | d.erdogmus@northeastern.edu | erdogmus@ece.neu.edu | Boston, MA | Image construction and analysis, vessel/tube network image analysis, feature extraction, multimodal biomarker discovery, machine learning for phenotyping, diagnosis and monitoring, mechanism-informed machine learning models for biological processes/dynamics. We can bring in extensive image, data analytics, computational modeling, and machine learning experience in all areas needed for successful execution. | We are looking to join a team that has relevant clinical/ biological expertise for TA1 and TA3, will complement with computational modeling, imaging, and analytics experience and expertise. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Johns Hopkins University | Sashank Reddy | sreddy6@jhmi.edu | ajohn273@jhu.edu | Baltimore, MD; Boston, MA; New York, NY | We use machine learning guided automated image analysis and feature detection methods to develop high resolution cellular and molecular maps of human tissues. We are applying these methods to lymphedema patient skin to uncover etiopathologic events driving disease development over time. Candidate drivers of lymphedema development are then tested in organ on a chip systems. Complementing this tissue level structural and transcriptomic analysis are prospective profiles of plasma in patients prone to lymphedema development. The overall goal of the lymphedema integrated network examination (LINE) consortium is to transform prediction and management of this devastating disorder. | We would welcome partners with complementary approaches in spatial transcriptomics and proteomics. We also welcome partners with a high volume of lymphedema patients. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction;Technical area 1: diagnosis and monitoring through biomarker discovery; |
| Memorial Sloan Kettering Cancer center | Raghu Kataru | katarur@mskcc.org | mehrarab@mskcc.org | New York | Our research group focuses on the lymphatic system in three different pathological settings: lymphedema, obesity, and cancer. Chronic lymphedema is a morbid disease condition without any cure. Our first goal is to uncover the pathology behind development and progression of cancer-related secondary lymphedema using mouse models and human biopsy samples. Briefly, we are interested in interaction of inflammatory cells (CD4+ T cells) with lymphatic vessels during lymphedema. Our ultimate aim is to come out with a therapeutic intervention to cure and prevent lymphedema by modulating CD4+ T cell inflammation and its negative effect on lymphatic vessels. Our second area of research is obesity, a state of systemic low-grade inflammation that also causes severe lymphatic damage and dysfunction. Our research is aimed at modulating lymphatic structure and function in obesity to reduce the systemic inflammation and obesity-related metabolic syndrome. Last but not the least, we are also interested in understanding the role of tumor lymphatic vessels and lymphatic function in modulating immune tolerance or antitumor immunity. | We are looking for other teams that help achieve our goals for visualizing lymphatic vessels, quantify lymphatic function in lymphedema and obesity. We are interested in collaborating teams that can help with early diagnosis of lymphedema using state-of-the art imaging tools. | Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery; |
| Figure 8 Federal | Scott Swilley, P.E. | scott.swilley@f8federal.com | tim.klawa@f8federal.com | Arlington, Virginia | Our focus areas include exposing ALL data types in their native formats for precise labeling in order to design and produce training and testing data sets against AI/ML models. | We are in search of partners requiring training data set design and production expertise/delivery. We have experience in labeling against medical imaging use cases. | Technical area 2: imaging technologies; |
| University of Washington / Seattle Childrens | Jimmy Bennett | jtbenn@uw.edu | Seattle WA | Seattle Children's is a leading center for treating vascular anomalies, including isolated and complex lymphatic anomalies. Our major expertise lies in genetic diagnosis, exemplified by our VANSeq test, which is currnently being performed on over 400 patients per year. VANSeq has significantly advanced our ability to diagnose and manage these conditions. We are at the forefront of research, conducting single cell and spatial transcriptomic analyses on both fresh and FFPE lymphatic tissues. Our access to high-quality tissue samples and detailed clinical data strengthens our research capabilities. While our focus is on genetic and molecular studies, we seek partnerships with teams skilled in animal models and advanced imaging methods to further enhance our understanding and treatment of vascular anomalies. | We seek partnerships with teams skilled in animal models and advanced imaging methods to further enhance our understanding and treatment of vascular anomalies. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| M3D, inc | Jerimy Polf | jerimy@m3dimaging.com | mike@m3dimaging.cim | Ann Arbor Michigan | We have and are developing hand-held gamma cameras that provide images of lymph nodes in under 10 seconds and can acquire serial images lymph flow and lymphatic drainage. | We are looking for partners that can help develop and identify new biomarkers and radiotracers, (which we can then partner with to image with new fast, portable gamma cameras) that can be used to image specific lymphatic disease. | Technical area 2: imaging technologies; |
| George Mason University | Siddhartha Sikdar | ssikdar@gmu.edu | Fairfax, VA | Chronic pain, lymphatic drainage in muscle. | Clinical expertise in human lymphatic imaging for musculoskeletal applications | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies; | |
| Physical Sciences Inc | Nick Iftimia | iftimia@psicorp.com | mujat@psicorp.com | Andover MA | We are developing high resolution optical imaging technologies, such as OCT, confocal microscopy, etc., which can be used to assess the lymphatic system through minimally invasive probes or noninvasively in the eye. See https://www.psicorp.com/research-development/biomedical-and-pharmaceutical/ | We are looking to team up with scientists and clinicians that may use our expertise in optical imaging. | Technical area 2: imaging technologies; |
| BostonGene | Anna Love | anna.love@bostongene.com | krystle.nomie@bostongene.com | Waltham, MA | BostonGene Corporation is a precision diagnostics company specializing in multi-omic biomarker discovery. BostonGene leverages ctDNA, ctRNA, immunoprofiling, multiplex immunofluorescence (MxIF), AI pathology, whole exome, and whole transcriptome sequencing technologies to shed light on actionable biomarkers for disease screening, diagnosis, prediction, and monitoring. In a recent Cancer Cell publication, we described using our peripheral blood-based immunoprofiling platform to define distinct immunotypes in healthy donors and cancer patients (PMID: 38744245). These immunotypes were associated with immunotherapy response in multiple cancer types. Our group also developed a multi-parametric biomarker combining the transcriptomic tumor microenvironment subtype with the genomic tumor mutational burden, the Tumor Immunity Portrait, which is predictive of immunotherapy response in non-small cell lung, bladder, melanoma, and gastric cancers (PMID: 34019806). Kassandra is an in-house cellular deconvolution algorithm designed to reconstruct sample composition (PMID: 35944503), while Helenus evaluates gene expression from the malignant cells to derive single-cell resolution from bulk RNA-seq data. Kassandra and Tumor Immunity Portrait are incorporated in our commercial laboratory-developed test, the Tumor Portrait, which additionally leverages our proprietary clinical decision-making support tools, Hippocrates and digitized NCCN Guidelines®. Ongoing work includes the development and validation of ML-based digital image analysis tools capable of detecting morphological and cellular features, including tertiary lymphoid structures and tumor-infiltrating lymphocytes, in H&E, IHC, and MxIF images. BostonGene’s research aims to improve patient outcomes by uncovering novel biomarkers and models that enhance diagnosis, screening, and management of lymphatic disorders and diseases. | BostonGene actively engages in innovative research with academic, clinical, and for-profit partners. For LIGHT, BostonGene is seeking teaming partners who share our vision for improving lymphatic disease diagnostic processes with a biomarker-driven approach. With our expertise in integrative multi-omics technologies, database development, and bioinformatics, ideal partners will have access to novel technologies and diverse patient cohorts for multi-modal biomarker discovery, model training, and adequate validation. Backed by an extensive dry lab, BostonGene's pipeline seamlessly integrates molecular, clinical (EHR), and imaging data. We value partnerships that complement our capabilities to accelerate the development and adoption of innovative diagnostic solutions. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction;Technical area 1: diagnosis and monitoring through biomarker discovery; |
| Rutgers Cancer Institute | Renata Pasqualini | renata.pasqualini@rutgers.edu | boswelwa@cinj.rutgers.edu | Newark, New Jersey | Our research group pioneered an innovative in vivo selection system using systemic administration of combinatorial libraries of compounds displayed on phage capsids. This platform allows isolation and identification of ligands (e.g., peptides, antibodies) that localize to specific organs and cellular compartments via the bloodstream or lymphatic fluid. Mechanistically, our work has shown that different tissues, whether healthy or diseased, have distinct molecular cell surface markers that circulating ligands can target selectively. This capability enables ligand-directed delivery of therapeutic or imaging payloads. Our approach systematically identifies and validates peptide ligands with specific affinities for receptors on target cell surfaces in their microenvironments. Our lab utilizes annotated tissue samples and data from selections in human patients and non-human primates, and high-throughput sequencing and bioinformatics analyses of organ/tissue-specific peptide motifs. Next, we focus on identifying the receptors targeted by validated ligands and characterizing their biological properties, including expression profiles and biochemical attributes. Our approach leverages our expertise and data mining strategies to build ligand-receptor pairs for thorough evaluation, particularly for imaging applications central to the ARPA-H LIGHT initiative. The data from in vivo phage display experiments, combined with biological samples and advanced "omics" technologies, will be examined using our bioinformatics pipeline. | We are open to partner with any institution/company for the development of ligand-directed imaging of lymphatic markers. Our technology is synergistic with multiple imaging modalities. We have expertise with IND filings and the FDA regulatory space, which would facilitate rapid translation into clinical trials within 5 years. | Technical area 1: diagnosis and monitoring through biomarker discovery; |
| University of North Carolina at Chapel Hill | Kathleen Caron | kathleen_caron@med.unc.edu | Chapel Hill, NC | Focused interest in G protein-coupled receptor pathways that govern lymphatic development, function and disease, using genetic animal models, human cell culture models and -omics approaches. | Interdisciplinary partners who wish to explore and translate basic science discoveries to the clinical medicine. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| biomodal | Donna McDade Walker | donna.mcdadewalker@biomodal.com | walraj.gosal@biomodal.com | Cambridge UK | biomodal is a life sciences tools company delivering the 6-base genome to better understand the dynamic nature of our epigenome and genome. To enable this, the company has developed core enzyme-based technology that can be deployed on various NGS platforms. The technology allows single-base-resolution 6-base sequencing and the interplay between genetics (A, C, G, T) and the epigenome (5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)) on the same molecule. biomodal provides multimodal information that allows greater power in identifying novel biomarkers, detecting molecular tumour changes, and monitoring disease evolution. Our customers are using the power of the 6-base genome to address fundamental questions in cancer research, neurodegenerative disease, non-invasive prenatal testing, aging and cardiovascular disease. | We are looking to team up with organisations who are looking to use genetics and epigenetics to apply a new lens to their biological/medical question and organisations with a unique platform that would be synergetic to ours to provide new solutions for biology and medicine. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Prenatal/Pediatric Congenital Lymphatic Anomaly Genetic Consortium/ Columbia University | Carrie Shawber | cjs2002@cumc.columbia.edu | New York, NY | Congenital lymphatic anomalies (LAs) are rare, often present in the fetal period, and can have severe morbidities and even mortality. LAs have been shown to be caused by germline and/or somatic mutations. However, the complete genetic picture of many LAs remains to be elucidated. Current genomic data sets at individual centers are not sufficiently powered for gene discovery and identification of modifying loci, leading to many studies identifying variants of uncertain significance (VOUS). Moreover, known pathogenic variants can have extreme heterogeneity in lymphatic phenotypes. Although a majority these cases present in the fetal period, methods to identify somatic mutations have yet to be developed. We are bringing together a multicentered team to study the genetics of prenatal and pediatric lymphatic anomalies by combining pre-existing data sets in a retrospective study and a prospective study using whole genome sequencing combined with mRNA sequencing and proteomics. Machine learning will be used to identify variants in known genes, novel genes and modifying loci. Variants will be screen using zebrafish models. We also aim to develop a diagnostic method to identify somatic variants in fetal lymphatic anomalies. The overall goal is to improve our understanding into the genetic underpinnings of LAs. | We are looking for teaming partners who will test their imaging technology and provide imaging data to be correlated with genetic findings in congenital lymphatic anomaly cases. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction;Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| University of California-Irvine | Sabee Molloi, Ph.D. | symolloi@uci.edu | Irvine, CA | Our current focus is to develop a noninvasive technique using contrast-enhanced CT lymphangiography to accurately measure the lymphatic flow rate. By utilizing a comprehensive low-dose CT technique, this technique enables simultaneous acquisition of CT lymphangiography images (anatomy) and measurement of lymphatic flow rate (physiology). | We are interested in collaboration with teams focusing on diagnosis, monitoring through biomarker discovery and prediction. | Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| Enveda Biosciences | Tendai Chisowa | tendai.chisowa@envedabio.com | kiana.west@envedabio.com | Boulder, CO | Enveda is a 5 year old, 250-person, private biotechnology company with expertise in metabolomics, drug discovery, and machine learning for the purpose of annotating the world's unknown chemistry. We know less than 1% of the planet's chemistry and less than 5% of the chemistry of the human body. Annotating human chemistry can unlock novel biomarkers for disease diagnostics. Our technology is capable of: 1. Using ML to discern and annotate the thousands of individual metabolites in a complex mixture without need for isolation or reference standards. 2. Feature linking: which enables us to track unique LC-MS signals across samples. We can detect similar patterns in metabolite profiles across a population of individuals with disease, enabling us to build metabolite signatures that are associated with variations of lymphatic disease. 3. Proprietary ML algorithms MS2Mol (takes a metabolite fingerprint and predicts its chemical structure) and MS2Prop (predicts chemical properties from a metabolite fingerprint) enable us to annotate unknown chemistry at a scale that has not been achieved to date. Our algorithms work without need to isolate the compound from the fluid. 4. High throughput screening and robotics enable us to scale discovery and function through phenotypic and target assays to answer the question "what does each molecule do". | While Enveda's platform is suited for novel discovery of metabolites that may serve as biomarkers, we seek partners with clinical expertise in lymphatic disease and/or imaging technologies that may pair with novel discovered metabolites and aid with development of new diagnostics tools. | Technical area 1: diagnosis and monitoring through biomarker discovery; |
| SRI International | Krishnan Thyagarajan | krishnan.thyagarajan@sri.com | hannah.mazur@sri.com | Palo Alto, California | SRI International is a global leader in R&D located headquartered in Silicon Valley and has research centers across the country. We have a rich history of supporting multi-million-dollar government and industry projects including in the biosciences, pharmaceutical, sensors, optoelectronics, and computational biology domains. As an independent nonprofit research institute, we have supported >200 drugs/vaccines/devices that have gone to clinical trials with 24 products that have made it to market with our data; have more than 15 years of experience in biomarker discovery and validation, point-of-care diagnostics, X-rays, magnetics; more than 30 years of expertise in optics, photonic signal processing, magnetic field sensing, fluorescence imaging with licensed products on the market; and more than 20 years of expertise in AI/ML and computational biology. We possess clinical trial facilities, which operates a state-of-the-art facility to provide early-stage human research capabilities for new medicines and medical devices. SRI’s facility occupies ~9,400 sq. ft expansion in Plymouth, MI. The facility is staffed with clinical pharmacologists, chemists, physician assistants, nurses and medical doctors, regulatory, quality assurance, and immunology services. | We are interested in partners and are seeking for TA1/TA2: medical professionals with expertise in the lymphatic system and access to potential members for the Discovery Duos, OEM/Medical manufacturer in the X-Ray/MRI space, team members with extensive access to tissue samples, and targeted contrast-agent development. For TA3: we are seeking medical organizations with access to a large volume of electronic health records or archived/recruiting samples from relevant patients with lymphatic disorders with or without concurrent disease(s) for data analyses. | Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery; |
| Judy.ai | Eean patterson | eean@judy.ai | Phoenix AZ | Judy is a general AI office tool for patient users and an EHR for Birthing Centers. Judy offers AI assisted point of care using DSM5 connected EHR with connected hardware to assist people and healthcare professionals in training and assessing health related issues. Specifically maternal care, Psychology, Specimen Stem collection, and preventive medicine. | Judy.ai and StratumHouse( birthcenter) seeks support in the preparation of a stem cell guidelines, Birthing Facility guidelines, blood and specimen guidelines, clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that explore and enable the evaluation of the Judy AI EHR in collection of Specimens (e.g stem cells) from women. | Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction;Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| MOXI Lab – Department of Medical Physics, University of Wisconsin – Madison /CDOSE Optics | Professor Brian Pogue | mochoa2@wisc.edu | bpogue@wisc.edu | Madison, Wisconsin, USA | Our current research and technology focus on real-time imaging of hypoxia across various tissues. We are particularly interested in applications related to surgical guidance through tumor hypoxia, as well as the monitoring and understanding of the naturally hypoxic lymphatic system. These tissues can be imaged in real-time using time-domain cameras developed by our industry partners, DOSEOptics, and by employing delayed fluorescence of PpIX, which is directly linked to oxygen quenching. Additionally, our lab aims to understand the effects of conventional and FLASH radiotherapy treatments in relation to oxygen across tissues. | Our team is enthusiastic about collaborating with other groups that can contribute to the mission of the LIGHT program. We are particularly interested in partners who have reproducible in vitro and in vivo animal models of the lymphatic system. Additionally, we welcome collaborations with teams that have clinical expertise in lymphedema and other lymphatic disorders. | Technical area 2: imaging technologies; |
| University of Texas at Dallas and UT Southwestern Medical Center | Zhenpeng Qin | Zhenpeng.Qin@utdallas.edu; Zhenpeng.Qin@utsouthwestern.edu | Dallas, TX | We have developed an enzyme- and compartment-free digital plasmonic nanobubble detection platform (DIAMOND) for single biomolecular detection. DIAMOND employs gold nanoparticles (AuNPs) for nanobubble generation through laser pulses, leveraging the intense light scattering from the nanobubble for instant signal amplification and detection. The platform combines lasers with microfluidics to generate a "virtual detection zone," enabling compartment-free digital counting with high-throughput analysis. The DIAMOND platform has shown attomolar sensitivity in protein biomarkers and has the potential for highly multiplexed detection. The sensitivity of DIAMOND-P is comparable to digital ELISA (dELISA), but it doesn't need enzymes to make the signal stronger or the complicated process of microscale compartmentalization. This enzyme- and compartment-free method greatly simplifies traditional processes, allowing for room-temperature assays with small sample volumes. | We are interested in teaming partners in all TA including lymphatic disease biomarker discovery (TA1), and genetics and models (TA3). | Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| University of Alberta | Roger Zemp | rzemp@ualberta.ca | Edmonton, Alberta, Canada | We have demonstrated in vivo 2D/3D photoacoustic imaging of lymphatic pumping [A. Forbrich et al., J Biomed Opt. 2017 Oct;22(10):1-6. doi: 10.1117/1.JBO.22.10.106003.]. We are currently developing new large-area 2D electrostrictive row-column ultrasound array technologies which offers readout from every element of the arrays using only row-column addressing in combination with bias-voltage aperture encoding. These are being commercialized by startup CliniSonix Inc. These arrays should enable panoramic 3D ultrasound/photoacoustic imaging of lymphatics and blood vessels to depths of a few cm in realtime. These arrays can also be made transparent for through illumination and pairing with NIR fluorescence imaging. We also have experience developing nanodroplet contrast agents and have experience with detecting biomarkers from cells and tissues and with detection of circulating tumor cells using novel methods. | We are looking for (1) clinical partners willing to discuss unmet needs and assist with clinical translation (2) contrast agent teams who have multi-modal agents close to clinical translation (3) lymphatic experts who could help tell a compelling story if we enable image-guided fine-needle aspiration of lymphatic fluids. (4) basic scientists who could help propose animal experiments to modulate lymphatic pumping (5) NIR fluorescence imaging teams who are open to joining efforts. (7) micro-surgeons who would like improved pre-planning of micro-surgeries involving lymphatics (6) CRO's who could help with commercialization and FDA approvals. | Technical area 2: imaging technologies; | |
| George Mason University | Parag Chitnis | pchitnis@gmu.edu | rvenezia@gmu.edu | Fairfax, VA | We are developing novel contrast agents for deep-tissue optical and photoacoustic imaging. These contrast agents are highly tunable in terms of size, charge, functionality, targeting, and are amenable for visualizing the lymphatic vessels with fine resolution and high sensitivity. | We are seeking partners who bring expertise in TA1 and/or TA3 as well as clinical experts who specialize in lymphatic disorders. | Technical area 2: imaging technologies; |
| University of Wisconsin Madison | Brian Pogue | mochoa2@wisc.edu | bpogue@wisc.edu | Madison, Wisconsin | Our current research and technology focus on real-time imaging of hypoxia across various tissues. We are particularly interested in applications related to surgical guidance through tumor hypoxia, as well as the monitoring and understanding of the naturally hypoxic lymphatic system. These tissues can be imaged in real-time using time-domain cameras developed by our industry partners, DOSEOptics, and by employing delayed fluorescence of PpIX, which is directly linked to oxygen quenching. Additionally, our lab aims to understand the effects of conventional and FLASH radiotherapy treatments in relation to oxygen across tissues. | Our team is enthusiastic about collaborating with other groups that can contribute to the mission of the LIGHT program. We are particularly interested in partners who have reproducible in vitro and in vivo animal models of the lymphatic system. Additionally, we welcome collaborations with teams that have clinical expertise in lymphedema and other lymphatic disorders. | Technical area 2: imaging technologies; |
| Field Viewers Inc | Sachin S Junnarkar, Ph.D | junnarkar@fieldviewers.com | Austin TX | Field Viewers Inc., operating under the Health Lync brand, specializes in developing cutting-edge technology solutions across various sectors including healthcare, military applications, and consumer electronics. Our core expertise lies in mixed-signal ASIC design, which supports advanced functionalities in small-scale, power-efficient devices. We excel in creating embedded IoT systems that are optimized for edge connectivity, enabling seamless integration and real-time data processing. In the cloud computing arena, we deliver robust, scalable solutions that ensure reliable data management and analytics capabilities. Our artificial intelligence and machine learning innovations are tailored to enhance decision-making processes and operational efficiencies. Additionally, we develop mobile applications for both iOS and Android platforms, focusing on HIPAA-compliant secure development to ensure the utmost protection of sensitive health data. Our comprehensive approach combines these technologies to offer innovative solutions that are not only secure and efficient but also adaptable to the specific needs of our clients, ranging from healthcare providers to military operations. Field Viewers Inc. is dedicated to pushing the boundaries of what is possible, driving forward advancements that integrate technology seamlessly into everyday applications for improved outcomes. | Field Viewers Inc. seeks to collaborate with innovative partners who are committed to excellence and share our vision of transforming healthcare applications through advanced technology. Ideal partners would bring expertise in areas such as biotechnology, healthcare analytics, medical device manufacturing, and cybersecurity. We value partners who offer complementary skills in AI and machine learning, cloud-based solutions, and mobile application development to enhance our existing platforms. We look for teaming partners who demonstrate a strong track record in regulatory compliance and ethical standards, especially those experienced in navigating complex healthcare and defense environments. A commitment to robust and secure data handling practices is crucial, as is experience with HIPAA compliance and other relevant legal frameworks. Collaborative spirit, innovative thinking, and the ability to scale operations efficiently are essential qualities we seek. Our goal is to engage with partners who are adaptable and responsive to the dynamic needs of the sectors we serve, enabling us to deliver integrated, cutting-edge solutions that advance the quality of care and operational effectiveness. | Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 2: imaging technologies;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; | |
| LY.SEARCH gGmbH | Manuel Cornely | info@cornely.org | cornely@lysearch.de | Duesseldorf Germany | Fundamental scientific research on lymphological diseases and patient-oriented improvement on diagnosis and treatment. The purpose of the organisation is the promotion of public health in particular research into lymphological diseases and the improvement of therapeutic options. The aim is also to simplify reliable diagnosis and to achieve an improvement in treatment and disease management in applied lymphology, as well as to increase public awareness in order to create a future awareness that those affected are not alone with their disease, but can receive targeted help of various kinds. | Our research partners are universities and clinics in Leipzig, Cologne, Bonn, Hamburg, Düsseldorf, Vienna (AUT), and Innsbruck (AUT). We work together with the Helmholtz-Institute in Leipzig, the Charité in Berlin, the Lymph Specialist Clinic Wolfsberg (AUT), the Lipedema Foundation and the LWA. | Technical area 2: imaging technologies;Technical area 1: diagnosis and monitoring through biomarker discovery;Technical area 3: prevention, prediction, and diagnostic confirmation through genetics, epigenetics, and models of lymphatic dysfunction; |
| Calliope Biophysics | Michael Bennett | mbenne56@gmail.com | Orem, UT | We have pioneered a technique that uses high-frequency ultrasound to detect biomarkers in tissue (including cancer tumors and sentinel lymph nodes) that denote the presence of cancer. We are now working to develop this technique into a device that can be used in vivo, allowing physicians to have confidence a removed lymph node was cancerous and can allow for preserving healthy lymph nodes within the body. | We are interested in collaborating with TA2 or TA3 focused teams, ideally also utilizing ultrasound in novel applications. We have experience in regulatory and product development, and are looking for partners who can reinforce our clinical outreach and fulfill the requirements of the Discovery Duos. | Technical area 1: diagnosis and monitoring through biomarker discovery; | |
| Oregon State University | Marilyn Mackiewicz | mackiewm@oregonstate.edu | David.Dickson@oregonstate.edu | Corvallis, Oregon | Our research focuses on two primary agendas: the development of safe nanomaterials (NMs) for clinical translation; and constructing a systems-level understanding of nanoparticle-biological interactions (NBIs) and toxicity. To solve multivariate challenges in nanotechnologies, I have iteratively evolved NMs closer to clinical translation, by designing NMs with bioinspired ligands enabling tunable libraries of NMs for the nanomedicine community. We have also discovered parameters for safer NMs design with minimal human and environmental impact. This unique design strategy is adaptable for safer NMs design for the broader nanomedicine community for use as cell labeling agents, drug delivery vehicles, and imaging agents. Through the use of our hybrid lipid membrane strategy, we are able to develop multi-functional NMs and stabilize gold, silver, and bismuth nanoparticles which can be used for drug delivery and imaging applications such as Optical coherence tomography imaging and X-ray CT imaging. We are currently working on designs that allow us to label therapeutic stem cells and target triple-negative breast cancer. | We are looking for partners and teams that will allow us to move our imaging technologies closer to clinical translation, either as drug delivery agents or imaging agents. We are also interested in teams that can partner with us to advance their technologies and who need chemists to design and target specific tissues, organics, or cells. | Technical area 2: imaging technologies; |